Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Interventional Oncologic Therapies
share announcement

Advances in Interventional Oncologic Therapies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 November 2024 | Viewed by 3409

Special Issue Editors

Dr. Edward W. Lee

E-Mail Website
Guest Editor
Ronald Reagan UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA 90095, USA
Interests: cancer therapy; treatment; arterial and venous embolization; interventional radiology; cancer biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Dong Il Gwon

E-Mail Website
Co-Guest Editor
Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea
Interests: vascular & non-vascular interventional radiology

Special Issue Information

Dear Colleagues,

Interventional oncologic therapies (IOT) have become an essential part of cancer treatment, encompassing essentially all cancer types including cancer of the liver, prostate, breast, colon, lung, kidney and pancreas. It has evolved from basic biopsy of a newly found mass to diagnose a cancer to complex endovascular cancer treatment with a curative intent such as radioembolization in liver primary cancer patients.  With personalized medicine and the advancement of immunotherapy in cancer treatment, interventional oncologic therapies have also progressively advanced in terms of the method of treatment, science behind each technique and availability of clinical outcome data.     

In this Special Issue, “Advances in Interventional Oncologic Therapies”, we aim to collaborate and share the newest, cutting-edge research, clinical trials, and comprehensive systemic reviews including meta-analysis on some of the interventional oncologic therapies.  Some of the topics we hope to include are:

  1. Basic and translational science research on interventional oncologic therapies
  2. New interventional oncologic therapies
  3. Cancers
    (a) Liver
    (b) Kidney
    (c) Pancreas
    (d) Lung
    (e)Prostate
    (f) Breast
    (g) Thyroid
    (h) Bone
    (i) Others
  4. Endovascular tumor treatment
    (a) Radioembolization
    (b) Chemoembolization
    (c) Other embolic oncologic therapies
  5. Tumor ablation
    (a) Microwave ablation
    (b) Cryoablation
    (c) Irreversible electroporation
    (d) Histotripsy
    (e) HIFU
    (f) RFA
    (g) H-FIRE
    (h) Other ablative therapies

Dr. Edward W. Lee
Dr. Dong Il Gwon
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 9505 KiB  
Article
Local Recurrence following Radiological Complete Response in Patients Treated with Subsegmental Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
by Dong Il Gwon, Gun Ha Kim, Hee Ho Chu, Jin Hyoung Kim, Gi-Young Ko and Hyun-Ki Yoon
Cancers 2023, 15(20), 4991; https://doi.org/10.3390/cancers15204991 - 14 Oct 2023
Cited by 1 | Viewed by 1121
Abstract
The aim of this study was to determine the local recurrence (LR) rate and identify factors associated with LR in patients who achieve a radiological complete response (CR) after undergoing balloon-occluded transcatheter arterial chemoembolization (B-TACE) for hepatocellular carcinoma (HCC). From November 2017 to [...] Read more.
The aim of this study was to determine the local recurrence (LR) rate and identify factors associated with LR in patients who achieve a radiological complete response (CR) after undergoing balloon-occluded transcatheter arterial chemoembolization (B-TACE) for hepatocellular carcinoma (HCC). From November 2017 to September 2021, 60 patients (44 men, 16 women; mean age, 63.5 years; range, 39–82 years) with 72 HCCs (mean diameter, 31 mm; range, 10–50 mm) who underwent subsegmental B-TACE were included in this retrospective study. Radiological and clinical evaluation of oily subsegmentectomy, defined as radiological CR of the HCC and peritumoral parenchymal necrosis, was performed. The CR rate was 97.2% (70 of 72 HCCs) at first follow-up (mean, 41 days; range, 14–110 days). Overall, 13 HCCs (19.7%) demonstrated LR at a mean of 29.8 months (range, 3–63 months) and cumulative LR rates were 1.5% 14.2% 21%, 21%, and 21% at 6, 12, 24, 36, and 48 months, respectively. In 28 (38.9%) of 72 HCCs, oily subsegmentectomy was achieved, tumor markers were normalized, and LR did not occur. The oily subsegmentectomy-positive group had a significantly lower LR rate than the oily subsegmentectomy-negative group (p = 0.001). Age ≥65 years (adjusted hazard ration (HR), 0.124; 95% confidence interval (CI), 0.037–0.412; p < 0.001) and peripheral location (adjusted HR, 0.112; 95% CI, 0.046–0.272; p < 0.001) were independent predictive factors of LR. Subsegmental B-TACE can be an effective method with a high initial CR rate and low LR incidence. Oily subsegmentectomy can be considered as an index of successful treatment because it did not demonstrate any LR. Full article
(This article belongs to the Special Issue Advances in Interventional Oncologic Therapies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

29 pages, 399 KiB  
Review
Advances in Image-Guided Ablation Therapies for Solid Tumors
by Warren A. Campbell IV and Mina S. Makary
Cancers 2024, 16(14), 2560; https://doi.org/10.3390/cancers16142560 - 17 Jul 2024
Cited by 1 | Viewed by 1496
Abstract
Image-guided solid tumor ablation methods have significantly advanced in their capability to target primary and metastatic tumors. These techniques involve noninvasive or percutaneous insertion of applicators to induce thermal, electrochemical, or mechanical stress on malignant tissue to cause tissue destruction and apoptosis of [...] Read more.
Image-guided solid tumor ablation methods have significantly advanced in their capability to target primary and metastatic tumors. These techniques involve noninvasive or percutaneous insertion of applicators to induce thermal, electrochemical, or mechanical stress on malignant tissue to cause tissue destruction and apoptosis of the tumor margins. Ablation offers substantially lower risks compared to traditional methods. Benefits include shorter recovery periods, reduced bleeding, and greater preservation of organ parenchyma compared to surgical intervention. Due to the reduced morbidity and mortality, image-guided tumor ablation offers new opportunities for treatment in cancer patients who are not candidates for resection. Currently, image-guided ablation techniques are utilized for treating primary and metastatic tumors in various organs with both curative and palliative intent, including the liver, pancreas, kidneys, thyroid, parathyroid, prostate, lung, breast, bone, and soft tissue. The invention of new equipment and techniques is expanding the criteria of eligible patients for therapy, as now larger and more high-risk tumors near critical structures can be ablated. This article provides an overview of the different imaging modalities, noninvasive, and percutaneous ablation techniques available and discusses their applications and associated complications across various organs. Full article
(This article belongs to the Special Issue Advances in Interventional Oncologic Therapies)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop